Home W. L. Gore & Associates Inc.

W. L. Gore & Associates Inc.

GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL Receives FDA Approval

The GORE® ACTIVE CONTROL System provides controlled, two-stage deployment, with primary deployment to an intermediate diameter and a secondary deployment to full diameter. This design allows for continuous blood flow throughout the deployment with multiple opportunities to visualize and refine graft placement. It is also designed to allow for angulation of the proximal end of the device for improved seal and apposition. It gives physicians added precision in placement and angulation so they can take full advantage of the exceptional conformability of the Gore device and confidently provide a minimally-invasive solution to more patients.

Gore Introduces GORE® TAG® Conformable Thoracic Stent Graft with Reduced Profiles in Europe

“As the market for TEVAR has continued to expand and evolve, lower profile devices have rapidly emerged with a goal of increased patient applicability, accessibility, trackability and finally reducing access complications for patients with smaller vessels,” said Professor Boeckler.

Gore to Highlight Real-World Aortic Data at 45th Annual VEITHsymposium®

The company is featuring the data in multiple presentations facilitated by lead investigators. GREAT is the largest industry-sponsored registry of aortic stent grafts with enrollment and follow-up data from over 100 sites across 13 countries.

First Patient in Europe Receives Implant of GORE® EXCLUDER® Conformable AAA Endoprosthesis with ACTIVE CONTROL System

“Before this device, EVAR was reserved for patients whose aorta fell within a standard shape and size,” said Prof. van Sambeek. “The conformability of the new GORE EXCLUDER Conformable Device in combination with the angulation control of the new delivery system will allow us to offer a less invasive, lower-risk alternative to open surgery to more AAA patients than ever before. The EXCeL registry will track the real-world effectiveness and safety of the device, and I look forward to enrolling additional patients with challenging, highly angulated aortic anatomies and seeing the long-term value of this device.”

FDA Approves GORE® CARDIOFORM Septal Occluder for PFO Closure to Prevent Recurrent Ischemic Stroke

Gore REDUCE Clinical Study demonstrated 77 percent relative reduction in recurrent ischemic stroke when PFO closure was combined with antiplatelet therapy, compared to antiplatelet therapy alone.

Gore Innovation Center Enters Joint Development Agreement with Kenzen

By incorporating Gore's advanced materials, Kenzen will enhance the comfort of these on-skin applications.

Gore Launches Anti-Migration Assurance Program for GORE® VIABIL® Short Wire Biliary Endoprosthesis

HOME W. L. Gore & Associates, Inc. (Gore) announced today the launch of its Anti-Migration Assurance Program for the GORE® VIABIL® Short...

GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion May Reduce Portal Hypertension Readmissions in Ongoing Study

HOME The GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion, a new device configuration developed by W. L. Gore & Associates, Inc. (Gore),...

First-in-Human Use of GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System for TEVAR

  New delivery system provides controlled and predictable placement of Gore’s highly conformable and time-tested stent graft W. L. Gore & Associates, Inc. (Gore) today announced...

W. L. Gore & Associates, Inc. Enhances VNA Test Assembly To Solve 70 GHz Challenges

W. L. Gore & Associates (Gore) has expanded the functional frequency range of its “FF series” GORE® VNA Microwave/RF Test Assemblies, now offering stable,...

Gore & Associates Receives FDA Clearance for GORE® SYNECOR Preperitoneal Biomaterial Hernia Repair Device

HOME W. L. Gore & Associates, Inc. (Gore) has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its GORE® SYNECOR...

GORE® EXCLUDER® Iliac Branch Endoprosthesis Approved in Japan

Takao Ohki, MD, PhD, Chairman and Professor of the Department of Surgery at Jikei University School of Medicine in Tokyo, who successfully performed...

Gore Announces Positive Results from REDUCE Clinical Study for PFO Closure

HOME Study met its primary endpoint with PFO closure in conjunction with antiplatelet therapy, reducing recurrent stroke by > 75% over antiplatelet...

Gore Joins Americas Hernia Society Quality Collaborative (AHSQC) as Silver Sponsor

HOME W. L. Gore & Associates, Inc. has joined the Americas Hernia Society’s Quality Collaborative (AHSQC) as a Silver Level Foundation Partner....

GORE® TIGRIS® Vascular Stent Gains Health Canada Approval for Treatment of Peripheral Artery Disease

The newly-approved GORE TIGRIS Vascular Stent uses a dual component structure, made from a single-wire nitinol stent with flexible and biocompatible fluoropolymer interconnections

FDA Approves First Balloon Expandable Stent Graft

“The VBX Stent Graft demonstrated notable immediate and nine-month safety and efficacy in treating patients with iliac occlusive disease which can be attributed to the exceptional device design,” said Jean Bismuth, MD. Dr. Bismuth continued, “Overall, there were multiple clinical benefits observed, including no median change in the device length upon deployment and a 100 percent technical success rate with no occurrences of stent dislodgement or significant residual stenosis. The study device performed well in disadvantaged lesions, including occlusions, which speaks to its trackability, radial strength, conformability, and stent retention.”

Must Read

Endotronix Enrolls First Patient in SIRONA II CE Mark Trial

“SIRONA II builds on the success of our First-in-Human trial and expands our experience with the Cordella Sensor as we progress towards receiving our CE Mark,” stated Katrin Leadley, MD, Chief Medical Officer of Endotronix.

Joe Montana Professional Football Hall of Famer Joins Stimwave Technologies As Official Spokesperson

“After years of dealing with the residual effects of my professional football career, I am excited to have found this battery-free, minimally-invasive alternative to opioids that relieves chronic pain and I’m eager to help other chronic pain sufferers receive this life-changing micro-implant,” said Montana.

Interventional Neurology: Carotid Artery Stents and Embolic Protection Systems Market Forecast

This medical market and technology report provides a comprehensive discussion of the global market for carotid artery stents and embolic protection systems.